Logo image of ENVB

ENVERIC BIOSCIENCES INC (ENVB) Stock Fundamental Analysis

NASDAQ:ENVB - Nasdaq - US29405E2081 - Common Stock - Currency: USD

1.5  -0.08 (-5.06%)

Fundamental Rating

2

Taking everything into account, ENVB scores 2 out of 10 in our fundamental rating. ENVB was compared to 195 industry peers in the Pharmaceuticals industry. ENVB scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. ENVB does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

ENVB had negative earnings in the past year.
In the past year ENVB has reported a negative cash flow from operations.
In the past 5 years ENVB always reported negative net income.
In the past 5 years ENVB always reported negative operating cash flow.
ENVB Yearly Net Income VS EBIT VS OCF VS FCFENVB Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -10M -20M -30M -40M

1.2 Ratios

The Return On Assets of ENVB (-205.75%) is worse than 89.78% of its industry peers.
With a Return On Equity value of -249.45%, ENVB is not doing good in the industry: 74.73% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -205.75%
ROE -249.45%
ROIC N/A
ROA(3y)-228.5%
ROA(5y)-175.33%
ROE(3y)-413.37%
ROE(5y)-299.5%
ROIC(3y)N/A
ROIC(5y)N/A
ENVB Yearly ROA, ROE, ROICENVB Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -200 -400 -600 -800

1.3 Margins

ENVB does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ENVB Yearly Profit, Operating, Gross MarginsENVB Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 20 -20 -40

More info and screens

6

2. Health

2.1 Basic Checks

The number of shares outstanding for ENVB has been increased compared to 1 year ago.
ENVB has more shares outstanding than it did 5 years ago.
ENVB has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
ENVB Yearly Shares OutstandingENVB Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 500K 1M 1.5M 2M 2.5M
ENVB Yearly Total Debt VS Total AssetsENVB Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M 40M 50M

2.2 Solvency

Based on the Altman-Z score of -23.81, we must say that ENVB is in the distress zone and has some risk of bankruptcy.
ENVB has a worse Altman-Z score (-23.81) than 88.17% of its industry peers.
ENVB has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -23.81
ROIC/WACCN/A
WACCN/A
ENVB Yearly LT Debt VS Equity VS FCFENVB Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 10M -10M 20M

2.3 Liquidity

A Current Ratio of 5.17 indicates that ENVB has no problem at all paying its short term obligations.
ENVB has a Current ratio of 5.17. This is in the better half of the industry: ENVB outperforms 66.13% of its industry peers.
A Quick Ratio of 5.17 indicates that ENVB has no problem at all paying its short term obligations.
ENVB's Quick ratio of 5.17 is fine compared to the rest of the industry. ENVB outperforms 67.74% of its industry peers.
Industry RankSector Rank
Current Ratio 5.17
Quick Ratio 5.17
ENVB Yearly Current Assets VS Current LiabilitesENVB Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M

More info and screens

1

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 76.04% over the past year.
EPS 1Y (TTM)76.04%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-176.92%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

ENVB is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 21.32% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y74.54%
EPS Next 2Y35.18%
EPS Next 3Y21.32%
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ENVB Yearly Revenue VS EstimatesENVB Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 50M 100M
ENVB Yearly EPS VS EstimatesENVB Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 -50 -100 -150

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ENVB. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ENVB. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ENVB Price Earnings VS Forward Price EarningsENVB Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ENVB Per share dataENVB EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -2 -4 -6 -8

4.3 Compensation for Growth

A more expensive valuation may be justified as ENVB's earnings are expected to grow with 21.32% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y35.18%
EPS Next 3Y21.32%

More info and screens

0

5. Dividend

5.1 Amount

ENVB does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ENVERIC BIOSCIENCES INC

NASDAQ:ENVB (2/11/2025, 11:35:59 AM)

1.5

-0.08 (-5.06%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-14 2024-11-14/amc
Earnings (Next)N/A N/A
Inst Owners5.67%
Inst Owner Change-16.08%
Ins Owners6.63%
Ins Owner Change15.77%
Market Cap15.26M
Analysts82.86
Price TargetN/A
Short Float %N/A
Short Ratio0.66
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)55.09%
Min EPS beat(2)54.75%
Max EPS beat(2)55.44%
EPS beat(4)4
Avg EPS beat(4)34.94%
Min EPS beat(4)6.72%
Max EPS beat(4)55.44%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)18.37%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 3.86
P/tB 3.95
EV/EBITDA N/A
EPS(TTM)-9.43
EYN/A
EPS(NY)-1.44
Fwd EYN/A
FCF(TTM)-0.8
FCFYN/A
OCF(TTM)-0.8
OCFYN/A
SpS0
BVpS0.39
TBVpS0.38
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -205.75%
ROE -249.45%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-228.5%
ROA(5y)-175.33%
ROE(3y)-413.37%
ROE(5y)-299.5%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 5.17
Quick Ratio 5.17
Altman-Z -23.81
F-Score6
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)103.19%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)76.04%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-176.92%
EPS Next Y74.54%
EPS Next 2Y35.18%
EPS Next 3Y21.32%
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y53.16%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year25.01%
EBIT Next 3YN/A
EBIT Next 5Y14.36%
FCF growth 1Y57.46%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y53.98%
OCF growth 3YN/A
OCF growth 5YN/A